It could be, as you say, 'a double edged sword' in a sense - as...

It could be, as you say, 'a double edged sword' in a sense - as it would point at some 'psychoactive' effect of CBD once it gets into the blood stream.
Zynerba has opted for transdermal delivery to avoid 'first-pass' liver metabolism (first-pass liver metabolism refers to the process by which the liver breaks down drugs ingested directly or indirectly through the gastrointestinal system, such as through oral or oral-mucosal delivery methods, allowing only a small amount of drug to be absorbed into the circulatory system).
Our BTXs formulations are designed to go into the skin but not into the blood circulation, BTXs doses are in percentages of CBD (2%-5%) while Zygel's doses are in mg (125mg and 250mg).
My point however was a speculative one: can Permatrex deliver higher percentages of CBD into the blood stream?
If so, considered as a TO target, Botanix's pipeline would present big pharma with the potential to carry Phase 3 trials for conditions beyond the field of dermatology, and chances are that they're already considering it.
Blockbuster drugs like Humira and Cosentyx due their popularity ( Cosentyx is at 3 billions USD revenue this year - up 35%) to the fact that are being prescribed for a number of conditions and apparently Novartis hasn't finished yet testing it for even more indications. Start at 6.30 minutes in the video interview: https://www.cnbc.com/video/2019/01/07/novartis-ceo-talks-endocyte-chasing-cures-over-profitable-treatments.html

IF the potential is there big pharma will sort it out.